Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 19/20 | 0.76 |
| ▸ | ADRB1 | P08588 | 18/20 | 0.76 |
| ▸ | ADRB2 | P07550 | 11/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7119163 | 0.95 | ADRB3 (0.79) | ADRB3ADRB1ADRB2 | |
| SCHEMBL9683368 | 0.94 | ADRB3 (0.74) | ADRB3ADRB1ADRB2MEN1MAPT | |
| SCHEMBL9683373 | 0.94 | ADRB3 (0.74) | ADRB3ADRB1ADRB2MEN1MAPT | |
| SCHEMBL7111902 | 0.90 | ADRB3 (0.76) | ADRB3ADRB1ADRB2MEN1MAPT | |
| SCHEMBL7115574 | 0.89 | ADRB3 (0.78) | ADRB3ADRB1ADRB2MEN1MAPT | |
| SCHEMBL7686851 | 0.89 | ADRB3 (0.78) | ADRB3ADRB1ADRB2MEN1MAPT | |
| SCHEMBL7097357 | 0.86 | ADRB3 (1.00) | ADRB3ADRB1ADRB2 | |
| SCHEMBL15275450 | 0.86 | ADRB3 (0.76) | ADRB3ADRB1ADRB2MEN1MAPT | |
| SCHEMBL27478454 | 0.86 | ADRB1 (0.78) | ADRB3ADRB1ADRB2MEN1KMT2A | |
| SCHEMBL7114736 | 0.85 | ADRB3 (0.79) | ADRB3ADRB1ADRB2MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6569873-B2 | Treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia, atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination | WYETH | 2003-05-27 | — | — | US | disclosed |
| US-20030055079-A1 | Azolidines as beta-3 adrenergic receptor agonists | WYETH | 2003-03-20 | — | — | US | disclosed |
| US-6465501-B2 | USEFUL IN TREATING OR INHIBITING METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA, ATHEROSCLEROSIS, GASTROINTESTINAL DISORDERS, NEUROGENETIC INFLAMMATION, GLAUCOMA, OCULAR HYPERTENSION AND INCONTINENCE | WYETH | 2002-10-15 | — | — | US | disclosed |
| US-20020032222-A1 | Azolidines as beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-14 | — | — | US | disclosed |
| WO-2002006258-A1 | AZOLIDINES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055079-A1 | Azolidines as beta-3 adrenergic receptor agonists | GPR119, ADRB1, ADRB3 | ADRB3 3/4885ADRB1 2/4885ADRB2 4/4885 |
| US-20020032222-A1 | Azolidines as beta-3 adrenergic receptor agonists | GPR119, ADRB1, ADRB3 | ADRB3 3/4885ADRB1 2/4885ADRB2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.